Skip Ribbon Commands
Skip to main content
Dr Chen Yunxin

Dr Chen Yunxin


Senior Consultant

Singapore General Hospital

Specialty: Haematology, Haematology

Clinical Interest: Lymphoma, Myeloma

Conditions Treated by this Doctor:
Acute Lymphocytic Leukemia (ALL), Aplastic Anaemia, Chronic lymphocytic leukemia, Chronic Myeloid Leukemia, Deep Vein Thrombosis, Deep Vein Thrombosis, Essential Thrombocythemia and Myelofibrosis, Lymphoma, Lymphoma Cancer, Multiple Myeloma, Myelodysplastic Syndrome, Myelofibrosis, Polycythemia Vera, Pulmonary Embolism, Thalassemia.

Clinical Appointments

  • Senior Consultant SingHealth Duke-NUS Blood Cancer Centre
  • Senior Consultant SingHealth Duke-NUS Transplant Centre
  • Senior Consultant Haematology Singapore General HospitalSingapore General Hospital
  • Senior Consultant National Cancer Centre SingaporeNational Cancer Centre Singapore


Dr Chen received her MBBS and Masters of Clinical Investigation from the Yong Loo Lin School of Medicine (NUS). She is a member of the Royal College of Physicians (UK) and a fellow of the Royal College of Pathologists (UK).  She completed specialist training in Haematology at Singapore General Hospital.

She specializes in care of patients with multiple myeloma and lymphoproliferative disorders. She also received the Health Manpower Development Programme (HMDP) award to train at Memorial Sloan Kettering Cancer Centre where she was involved in developing novel cellular therapeutics for treatment of multiple myeloma as well as myeloma CAR T-cell clinical trials. 

Within the SingHealth Duke-NUS Cell Therapy Centre, she is Education Co-Lead and Clinical Deputy Lead of Adult Blood Cancer. She has been involved in developing the clinical CAR T-cell programme at SingHealth Outram campus and outpatient transplant and home chemotherapy programs.


  • ​FRCPath (UK): 2016
  • MRCP (UK): 2011
  • MBBS (Singapore): 2008

Professional Appointments and Committee Memberships

  • Clinical Assistant Professor, DUKE-NUS Medical School
  • Clinical Lecturer, NUS YLL School of Medicine
  • Clinical Deputy Lead (Adult Blood Cancer) & Education Co-Lead, SingHealth Duke-NUS Cell Therapy Centre
  • Member, Singapore Multiple Myeloma Study Group
  • Core faculty, Haematology Senior Residency Programme


  • SingHealth Quality Service Award – Gold (2017)
  • MOH Healthcare Research Scholarship (2016)
  • SGH Moments Award (2013)
  • SingHealth Quality Improvement Project - Best Team (2013)

Research Interests


  • Chen Y, Nagarajan C, Tan MS, Martinelli G, Cerchione C. BCMA-targeting approaches for treatment of multiple myeloma. Panminerva Med [Internet]. 2021 Mar;63(1):28–36. 
  • Chen Y, Gopalakrishnan SK, Ooi M, Sultana R, Lim LH, Grigoropoulos N, et al. A phase 2 study of carfilzomib, cyclophosphamide and dexamethasone as frontline treatment for transplant-eligible MM with high-risk features (SGH-MM1). Vol. 11, Blood cancer journal. 2021. p. 150. 
  • Ong SY, de Mel S, Grigoropoulos NF, Chen Y, Tan YC, Tan MSY, et al. High-dose methotrexate is effective for prevention of isolated CNS relapse in diffuse large B cell lymphoma. Blood Cancer J [Internet]. 2021 Aug 12;11(8):143. 
  • Nagarajan C, Tan MS, Chen Y, Martinelli G, Cerchione C. Current and future perspectives of maintenance therapy in multiple myeloma. Panminerva Med [Internet]. 2020 Dec;62(4):225–33. 
  • Pwint K-SW, Chen Y, Diong CP, Goh Y-T, Grant D, Ho A, et al. Mobilization kinetics of peripheral blood stem cells with rescue plerixafor - real-world experience from a single center. Vol. 61, Leukemia & lymphoma. United States; 2020. p. 1740–3. 
  • de Larrea CF, Staehr M, Lopez A V, Ng KY, Chen Y, Godfrey WD, et al. Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma. Blood cancer Discov. 2020 Sep;1(2):146–54. 
  • Jain T, Knezevic A, Pennisi M, Chen Y, Ruiz JD, Purdon TJ, et al. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv. 2020 Aug;4(15):3776–87. 
  • Wang C, Soekojo CY, Mel S de, Ooi M, Chen Y, Goh AZK, et al. Natural History and Prognostic Factors at First Relapse in Multiple Myeloma. Cancers (Basel). 2020 Jul;12(7). 
  • Yeoh K-W, Thitsar SM, Master Z, Loh Y, Chen Y, Nagarajan C, et al. Pleural plasmacytomas - the role of radiotherapy. Vol. 190, British journal of haematology. England; 2020. p. e160–2. 
  • Desai J, Gan H, Barrow C, Jameson M, Atkinson V, Haydon A, et al. Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors. J Clin Oncol  Off J Am Soc Clin Oncol. 2020 Jul;38(19):2140–50. 
  • Soekojo CY, Wang G-M, Chen Y, Casan J, Wolyncewicz G, Lin A, et al. Role of Conventional Karyotyping in Multiple Myeloma in the Era of Modern Treatment and FISH Analysis. Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):e470–7. 
  • Phipps C, Lee YS, Ying H, Nagarajan C, Grigoropoulos N, Chen Y, et al. The impact of time from diagnosis to treatment in diffuse large B-cell lymphoma. Leuk Lymphoma. 2018 Oct;59(10):2336–41. 
  • de Mel S, Chen Y, Lin A, Soh TG, Ooi M, Yap ES, et al. Vinorelbine-Cyclophosphamide compared to cyclophosphamide in peripheral blood stem cell mobilization for multiple myeloma. Hematol Oncol Stem Cell Ther. 2018 Dec;11(4):225–32. 
  • Abid MB, De Mel S, Abid MA, Yap ES, Gopalakrishnan SK, Chen Y, et al. Pegylated Filgrastim Versus Filgrastim for Stem Cell Mobilization in Multiple Myeloma After Novel Agent Induction. Clin Lymphoma Myeloma Leuk. 2018 Mar;18(3):174–9. 
  • Chen Y, Law HY, Tan GP, Ang AL. Concurrent β-thalassaemia trait and Southeast Asian ovalocytosis associated with clinically significant iron loading. Vol. 63, Blood cells, molecules & diseases. United States; 2017. p. 25–6. 
  • de Mel S, Chen Y, Gopalakrishnan SK, Ooi M, Teo C, Tan D, et al. The Singapore Myeloma Study Group Consensus Guidelines for the management of patients with multiple myeloma. Singapore Med J. 2017 Feb;58(2):55–71. 
  • Chen Y, Tan S-Y, Petersson BF, Khor YM, Gopalakrishnan SK, Tan D. Occult recurrence of monomorphic epitheliotropic intestinal T-cell lymphoma and the role of MATK gene expression in diagnosis. Vol. 35, Hematological oncology. England; 2017. p. 852–5. 
  • Ong S-Y, Ng HY, Surendran S, Linn YC, Chen Y, Goh YT, et al. Subcutaneous bortezomib combined with weekly cyclophosphamide and dexamethasone is an efficient and well tolerated regime in newly diagnosed multiple myeloma. Vol. 169, British journal of haematology. England; 2015. p. 754–6. 
  • Phipps C, Chen Y, Gopalakrishnan S, Tan D. Daratumumab and its potential in the treatment of multiple myeloma: overview of the preclinical and clinical development. Ther Adv Hematol. 2015 Jun;6(3):120–7. 

Research Trials